Tyrus Capital S.A.M. Atea Pharmaceuticals, Inc. Transaction History
Tyrus Capital S.A.M.
- $10.5 Billion
- Q3 2023
A detailed history of Tyrus Capital S.A.M. transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Tyrus Capital S.A.M. holds 1,260,000 shares of AVIR stock, worth $4.62 Million. This represents 35.9% of its overall portfolio holdings.
Number of Shares
1,260,000
Previous 1,260,000
-0.0%
Holding current value
$4.62 Million
Previous $4.71 Billion
19.79%
% of portfolio
35.9%
Previous 33.11%
Shares
1 transactions
Others Institutions Holding AVIR
# of Institutions
119Shares Held
49.6MCall Options Held
108KPut Options Held
327K-
Black Rock Inc. New York, NY9.24MShares$33.9 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA6.15MShares$22.6 Million0.71% of portfolio
-
Bml Capital Management, LLC Zionsville, IN5.54MShares$20.3 Million14.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.72MShares$17.3 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA4.08MShares$15 Million2.01% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $306M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...